Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Could Lupin Ltd. be the next to sell off its India business to a multinational drug company? Sources report that Lupin is considering selling its India business for a deal valued at as much as $1 billion, and several market analysts in India say the question is not without merit
You may also be interested in...
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Eli Lilly Ropes In Lupin For A Big Push For Its Insulin Brands In India
MUMBAI - As Pfizer Inc. warms up for an entry into the rapidly growing Indian insulin market, Eli Lilly & Co., which is already established in the Indian market, is looking to strengthen its franchise via a strategic collaboration with Lupin Ltd. - an Indian company making significant strides in the anti-diabetes, cardiology, nephrology and respiratory segments
Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets